View Clinical Trial (Medical Research Study)

Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS) - NCT00868140-23298(Clinical Trial 280169)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Richmond
State:  
VA
Zip Code: 23298
Conditions: Polycystic Ovary Syndrome
Purpose: Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated DCI-IPG release. To assess the effects of a chronic reduction in circulating insulin on DCI metabolism, we propose to reduce circulating insulin in obese women with PCOS by improving insulin sensitivity with the drug pioglitazone. Pioglitazone is a thiazolidinedione that improves peripheral insulin sensitivity, presumably by activation of the PPARγ receptor.Administration of pioglitazone to women with PCOS has been shown to improve insulin sensitivity, reduce insulin secretion, and decrease both fasting and post-prandial serum insulin concentrations,
Study summary: This protocol focuses on the hypothesis that a deficiency in a putative inositolphosphoglycan (IPG) mediator of insulin action, namely a D-chiro-inositol-containing IPG (DCI-IPG), contributes to the insulin resistance of some women with PCOS. Our interest in this area stems directly from our previous studies, which demonstrated that administration of the precursor, D-chiro-inositol (DCI), to both obese23 and lean24 women with PCOS improved glucose intolerance while reducing circulating insulin, and simultaneously improved ovulatory function and decreased serum androgens. These findings were recently confirmed in a large-scale study by an independent group.25 The findings of these three studies suggested that administration of DCI improved insulin sensitivity in PCOS, which then resulted in an improved hormonal and metabolic milieu.
Criteria: Inclusion Criteria: 1. Obese (BMI greater than or equal to 30 kg/m2) women with PCOS between 18-40 years of age: - oligomenorrhea (less than 8 menstrual periods annually) - biochemical hyperandrogenemia (elevated total or free testosterone) - normal thyroid function tests and serum prolactin; AND - exclusion of 21a-hydroxylase deficiency by a fasting 17a-hydroxyprogesterone less than 200 ng/dl.51, 2. acceptable health on the basis of interview, medical history, physical examination, and laboratory tests (CBC, SMA20, urinalysis, negative pregnancy test). 3. Signed, witnessed informed consent. 4. Ability to comply with study requirements. Exclusion Criteria: 1. Diabetes mellitus by fasting glucose or OGTT, or clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease (other than non-melanoma skin cancer). 2. Current use of oral contraceptives. 3. Documented or suspected recent (within one year) history of drug abuse or alcoholism. 4. Ingestion of any investigational drug within two months prior to study onset.
Study is available at: Virginia Commonwealth University General Clinical Research Center
Richmond, VA 23298
United States

Primary Contact:
Terre Y. Williams
Email: tywillia@vcu.edu
Phone: 804-828-2663

Secondary Contact:
Terre Y. Williams
Email: tywillia@vcu.edu
Phone: 804 828-2663
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.